{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T01:02:25Z","timestamp":1789434145714,"version":"build-2803163510"},"reference-count":18,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,3,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The addition of high-dose cytarabine to rituximab\/bendamustine (RB) induction could improve outcomes for transplant-eligible patients with mantle cell lymphoma (MCL). We conducted a pooled analysis of 2 phase 2 trials and an off-trial cohort each testing 3 cycles of RB and 3 cycles of rituximab\/high-dose cytarabine (RC) followed by autologous stem cell transplantation (ASCT) among untreated, transplant-eligible patients with MCL. Dana-Farber Cancer Institute (DFCI) and Washington University in St. Louis (WUSTL) led separate phase 2 trials testing sequential and alternating cycles of RB\/RC, respectively. Patients treated at DFCI with sequential RB\/RC off trial were retrospectively identified. Minimal residual disease (MRD) was assessed in the DFCI trial. A total of 88 patients (23 DFCI trial, 18 WUSTL trial, and 47 off trial) received RB\/RC; 92% of patients completed induction, and 84% underwent planned consolidative ASCT. Grade 3 or 4 adverse events among trial patients included lymphopenia (88%), thrombocytopenia (85%), neutropenia (83%), and febrile neutropenia (15%). There were no treatment-related deaths during induction and 2 following ASCT. Among 87 response-evaluable patients, the end-of-induction overall and complete response rates were 97% and 90%, respectively. After a median follow-up of 33 months, 3-year progression-free survival and overall survival were 83% and 92%, respectively. Patients undergoing MRD testing experienced prolonged MRD negativity after ASCT with emergence of MRD occurring in only 1 patient who subsequently relapsed. RB\/RC followed by ASCT achieves high rates of durable remissions in transplant-eligible patients with MCL. These trials were registered at www.clinicaltrials.gov as #NCT01661881 (DFCI trial) and #NCT02728531 (WUSTL trial).<\/jats:p>","DOI":"10.1182\/bloodadvances.2019001355","type":"journal-article","created":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T13:38:54Z","timestamp":1583242734000},"page":"858-867","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":54,"title":["Rituximab\/bendamustine and rituximab\/cytarabine induction therapy for transplant-eligible mantle cell lymphoma"],"prefix":"10.1182","volume":"4","author":[{"given":"Reid W.","family":"Merryman","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Edwin","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Washington University School of Medicine, St. Louis, MO;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Redd","sequence":"first","affiliation":[{"name":"Department of Biostatistics, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jad","family":"Bsat","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Chase","sequence":"first","affiliation":[{"name":"Department of Medicine, Brigham and Women\u2019s Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7349-0176","authenticated-orcid":false,"given":"Ann","family":"LaCasce","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold","family":"Freedman","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caron","family":"Jacobson","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Fisher","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Ng","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Crombie","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oreofe","family":"Odejide","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Davids","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer R.","family":"Brown","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Jacene","sequence":"first","affiliation":[{"name":"Department of Imaging, Dana-Farber Cancer Institute, Boston, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Cashen","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Washington University School of Medicine, St. Louis, MO;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy L.","family":"Bartlett","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Washington University School of Medicine, St. Louis, MO;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5744-0670","authenticated-orcid":false,"given":"Neha","family":"Mehta-Shah","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Washington University School of Medicine, St. Louis, MO;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Ghobadi","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Washington University School of Medicine, St. Louis, MO;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Kahl","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Washington University School of Medicine, St. Louis, MO;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7251-8082","authenticated-orcid":false,"given":"Robin","family":"Joyce","sequence":"first","affiliation":[{"name":"Division of Hematology, Beth Israel Deaconess Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Armand","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Jacobsen","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,3,3]]},"reference":[{"issue":"4","key":"2020030311400368000_B1","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JCO.2008.16.8435","article-title":"Improvement of overall survival in advanced stage mantle cell lymphoma","volume":"27","author":"Herrmann","year":"2009","journal-title":"J Clin Oncol"},{"issue":"9","key":"2020030311400368000_B2","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","article-title":"Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)","volume":"23","author":"Lenz","year":"2005","journal-title":"J Clin Oncol"},{"issue":"9873","key":"2020030311400368000_B3","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"19","key":"2020030311400368000_B4","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"issue":"10044","key":"2020030311400368000_B5","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","article-title":"Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network","volume":"388","author":"Hermine","year":"2016","journal-title":"Lancet"},{"issue":"11","key":"2020030311400368000_B6","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1200\/JCO.2012.45.9842","article-title":"Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation","volume":"31","author":"Visco","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"2020030311400368000_B7","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S2352-3026(16)30185-5","article-title":"Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi","volume":"4","author":"Visco","year":"2017","journal-title":"Lancet Haematol"},{"issue":"1","key":"2020030311400368000_B8","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/bjh.13929","article-title":"A phase 2 study of rituximab-bendamustine and rituximab-cytarabine for transplant-eligible patients with mantle cell lymphoma","volume":"173","author":"Armand","year":"2016","journal-title":"Br J Haematol"},{"issue":"4","key":"2020030311400368000_B9","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"issue":"27","key":"2020030311400368000_B10","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"24","key":"2020030311400368000_B11","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1182\/blood-2015-03-635169","article-title":"Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing","volume":"125","author":"Kurtz","year":"2015","journal-title":"Blood"},{"issue":"26","key":"2020030311400368000_B12","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.1182\/blood-2012-07-444042","article-title":"Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia","volume":"120","author":"Faham","year":"2012","journal-title":"Blood"},{"issue":"7","key":"2020030311400368000_B13","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"issue":"6","key":"2020030311400368000_B14","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood-2005-07-2845","article-title":"Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma","volume":"107","author":"Pott","year":"2006","journal-title":"Blood"},{"issue":"16","key":"2020030311400368000_B15","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2009-06-230250","article-title":"Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study","volume":"115","author":"Pott","year":"2010","journal-title":"Blood"},{"issue":"4","key":"2020030311400368000_B16","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3324\/haematol.2011.050203","article-title":"Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909","volume":"97","author":"Liu","year":"2012","journal-title":"Haematologica"},{"issue":"3","key":"2020030311400368000_B17","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.bbmt.2016.12.634","article-title":"Molecular monitoring after autologous stem cell transplantation and preemptive rituximab treatment of molecular relapse; results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with median follow-up of 8.5 years","volume":"23","author":"Kolstad","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"13","key":"2020030311400368000_B18","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma","volume":"377","author":"Le Gouill","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/5\/858\/1717965\/advancesadv2019001355.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/5\/858\/1717965\/advancesadv2019001355.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T13:39:02Z","timestamp":1583242742000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/5\/858\/452603\/Rituximabbendamustine-and-rituximabcytarabine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,3]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,3,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019001355","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,3]]}}}